Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLM-102
- Development stage
- Phase 1
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PLM-102 is an orally bioavailable small molecule inhibitor of the Proviral Insertion site in Moloney murine leukemia virus (PIM) kinases, specifically targeting PIM1, PIM2, and PIM3. Developed at the M.D. Anderson Cancer Center, PLM-102 was designed to treat hematologic malignancies, particularly relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). PIM kinases are frequently overexpressed in these cancers and play a critical role in promoting cell survival, proliferation, and resistance to apoptosis through the phosphorylation of various downstream targets in the JAK/STAT and PI3K/AKT/mTOR pathways. By inhibiting PIM kinases, PLM-102 aims to induce cell cycle arrest and apoptosis in leukemic cells. Clinical development reached Phase I but was terminated by the sponsor due to a change in the development plan.
Beyond the preview
Go deeper on PLM-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLM-102.